作为癌细胞中诱导合成致死性的分子标,G-四重复DNA
Keith I E McLuckie1, Marco Di Antonio, Heather Zecchini
1Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, United Kingdom.
Journal of the American Chemical Society
|June 21, 2013
概括
皮里多斯塔丁 (PDS) 药物通过稳定G-四重复合体 (G4s) 来增强癌细胞死亡. 这种合成杀伤性方法在与DNA修复抑制剂相结合或在具有缺陷DNA修复通路的细胞中显示出有希望.
科学领域:
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 合成致命性涉及导致细胞死亡的基因组合突变.
- 皮里多斯塔丁 (PDS) 稳定了G-四重复合体 (G4s),诱导了DNA双链断裂 (DSB).
- 在具有DNA修复缺陷的细胞中,可以增强联体诱导的G4稳定.
研究的目的:
- 研究PDS与DNA修复抑制的协同效应.
- 评估PDS在具有受损同源复合 (HR) 和非同源末端结合 (NHEJ) 修复通路的细胞中的疗效.
主要方法:
- 利用定氨酸 (PDS) 来稳定癌细胞中的G-四复合体 (G4s).
- 评估了与DNA-PK抑制剂NU7441 (NHEJ通路) 的协同细胞死亡.
- 检查了BRCA2缺乏细胞 (受损HR通路) 中的PDS影响.
主要成果:
- 当PDS与NU7441结合时,PDS显示出协同作用的细胞死亡,抑制NHEJ.
- 缺乏BRCA2的细胞表现出对PDS的增强敏感性,表明与受损HR的协同作用.
- 这些发现突显了通过G4向和DNA修复抑制的合成致死性.
结论:
- 像PDS这样的G4向配体可以与DNA修复途径抑制协同作用.
- 这一战略有可能发展出新的癌症治疗方法.
- 通过G4稳定和DNA修复缺陷来准合成致命性,为癌症治疗提供了一个有希望的途径.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...